Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Healthcare >

Great Basin Scientific Inc. (GBSN)

Add GBSN Price Alert      Hide Sticky   Hide Intro
Moderator: Atlanta1, EnergySaver, TKane, kontente
Search This Board: 
Last Post: 6/23/2017 12:03:16 PM - Followers: 435 - Board type: Free - Posts Today: 1




PHONE: 801-990-1055TOLLFREE: 888-360-4022; CUSTOMER SUPPORT: 888-333-9793

***6/1/2017 NEWS UPDATE***

Data to be Presented June 1-5, 2017 at American Society of Microbiology's "Microbe 2017" Conference Demonstrates Great Basin Scientific, Inc.’s Stool Bacterial Pathogens Panel Efficacy
       Four posters describing the Company’s platform are to be presented, including a third-party (Laboratory Alliance of Central New York) clinical study poster of the Stool Bacterial Pathogens Panel 

SALT LAKE CITY, June 01, 2017 -- Great Basin Scientific, Inc. (GBSN), a molecular diagnostics company, announced today that it will present 3 posters describing the reliability and effectiveness of its diagnostic platform to attendees of American Society of Microbiology's (ASM) Conference "Microbe 2017" in New Orleans on June 1-5, 2017. Additionally, Dr. Paul Granato from the Laboratory Alliance of Central New York will present a poster summarizing the results of a multi-site independent clinical study evaluating the Great Basin Scientific, Inc. Stool Bacterial Pathogens Panel, which is awaiting 510(k) clearance from the US Food and Drug Administration (FDA). In the independent study by the Laboratory Alliance of Central New York, the Company’s Stool Bacterial Pathogens Panel is shown to process results in approximately 2 hours with superior detection rates of over 97%, compared to 51% for conventional culture and EIA methods.

***5/24/2017 NEWS UPDATE*** 


Great Basin Scientific Issued Second U.S. Patent for PCR Amplification Suppressor

SALT LAKE CITY, May 24, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc.(OTCQB:GBSN), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent 9,657,353 for the Company’s amplification suppressor. This patent is the second U.S. patent relating to Great Basin’s amplification suppressor technology, expanding the Company’s protection to assays, kits, and products. The protection afforded by this patent allows the Company to explore licensing of the technology to applications such as medical research, food safety, veterinary, and more.


***4/12/2017 NEWS UPDATE***

Announced today (4/12/2017) that it has received CE Marking for its Stool Bacterial PathogensPanel

***4/3/2017 NEWS UPDATE*** 
FDA 510(k) Premarket Notification - Effective 3/31/2017 - Great Basin Scientific, Inc. - Bordetella Pertussis DNA Assay System:

FYI (Why this particular diagnostic product is so important and useful for healthcare professionals): Pertussis, a respiratory illness commonly known as whooping cough, is a very contagious disease caused by a type of bacteria called Bordetella pertussis. These bacteria attach to the cilia (tiny, hair-like extensions) that line part of the upper respiratory system. The bacteria release toxins (poisons), which damage the cilia and cause airways to swell. Pertussis is a very contagious disease only found in humans. It is spread from person to person. People with pertussis usually spread the disease to another person by coughing or sneezing or when spending a lot of time near one another where you share breathing space. Many babies who get pertussis are infected by older siblings, parents, or caregivers who might not even know they have the disease.

GBSN's most recent 510(k) clearances and applications: 

Great Basin Scientific, Inc. (GBSN) granted 510(k) clearance 3/31/17 by the FDA for Great Basin Bordetella Direct Test

Great Basin Scientific, Inc. submits 510(k) application to FDA 12/19/16 for diagnostic Stool Bacterial Pathogens Panel.

Great Basin Scientific Reports Fourth Quarter and Full Year 2016 Results
(GlobeNewswire,  March 22, 2017, 07:03:00 AM EDT)

*Company reduces operating costs, improves gross margin and cash burn rate quarter-over-quarter *
Fourth quarter revenue increased 39% year-over-year; 2016 revenues increased 42%
14% reduction in net cash used in operating activities from the third quarter to the fourth quarter of 2016
34% reduction in fourth quarter G&A expenses leads to 4% reduction in total operating expenses compared to third quarter
Quarterly gross margin improved 42 basis points over third quarter to best level of the year
Percentage of customers using more than one assay increased 17% quarter-over-quarter and 81% year-over-year

SALT LAKE CITY, March 22, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:

GBSN), a molecular diagnostic company, today reported operating results for the fourth quarter and full year ended December 31, 2016.

"The fourth quarter of 2016 was a period of significant progress and change for Great Basin," said Ryan Ashton, co-founder and chief executive officer of Great Basin. "During the third quarter, research and development spending and gross margin inefficiency peaked as we invested in significant menu expansion, which included concurrently running two clinical trials and preparing for the commercial launch of two products that the U.S. Food and Drug Administration (FDA) cleared in early 2016. With those efforts either behind us or winding down, we turned our focus to improving operational efficiencies and implementing cost management programs in preparation for 2017. These efforts resulted in a reduction in sequential quarterly operating expenses and our strongest gross margins of the fiscal year. Furthermore, we expect that the changes we made in the fourth quarter—along with the January completion of the clinical trial for our Bordetella Direct Test and the restructuring and reduction plan we announced in early February—will result in further improvements to our operating expenses, burn rate and gross margins in the first half of 2017."

"Beyond the sequential improvements in gross margins and reduced operating expenses, 2016, overall, was a year of noteworthy progress for the Company. For the first time, we launched two new products and successfully completed two clinical trials in a single year. The doubling of our menu to four assays will promote our objective of continually expanding our customer footprint and increasing our revenue per customer."

Read more:







About Great Basin Scientific, Inc: Great Basin Scientific, Inc. (ticker symbol: GBSN) is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. Great Basin's molecular diagnostics system is uniquely capable of answering both the ‘What is it?’ question --answered by a low-cost, low-plex assay-- and the ‘What is causing it?’ question, identified by a multi-plex panel. Great Basin has FDA Clearance on tests for Clostridium difficile and Group B streptococcus. Low-plex tests in development include SA Nasal and Staph ID/R and multi-plex panels being developed include Fungal Pathogens, Shiga-toxin-producing E. coli (STEC) and Food-borne Pathogens (GI Panel). Great Basin Scientific’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. Fast, accurate results. More answers. One easy-to-use and cost-effective system. Only Great Basin delivers a powerful product pipeline of tests and panels that allows every lab to adopt molecular diagnostics that will assist clinicians in better diagnosing and managing patients outcomes. The company sells its diagnostic tests through a direct sales force in the United States, as well as through distributors in the European Union and New Zealand. Great Basin Scientific, Inc. is headquartered in Salt Lake City, UT. For more information on the company or its products, please feel free to contact us at our Corporate Headquarters.


Amended Statement of Ownership (sc 13g/a)
Date: January 24, 2017 @ 4:29 PM
Source: EDGAR (US Regulatory)
Stock: Great Basin Scientific, Inc. (QB) (GBSN)

 All iHub stock board posts are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting any content that is off-topic to the stock, which is the subject of the board;
*Posting focused on Admins, Moderators, Users, or post deletions are also off-topic;
*Posting comments, etc. that could be construed as a Personal Attack on another;
*Posting anything that is a Violation of Privacy (no stated consent) is also off-topic;

* Posting statements that are of no value to the stock discussion for board users; or
* When you violate any other posting term of the iHub User Agreement:
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GBSN News: Current Report Filing (8-k) 04/10/2017 09:02:48 AM
GBSN News: USMJ Experiencing High Volume On Verge Of PPS Breakout With Stock Rated Very Bullish And Major Short Position Getting Squeezed 04/06/2017 11:49:40 AM
GBSN News: Annual Report (10-k) 03/22/2017 07:18:09 AM
GBSN News: Current Report Filing (8-k) 03/22/2017 07:01:46 AM
GBSN News: Current Report Filing (8-k) 03/10/2017 07:17:42 AM
#36957  Sticky Note Good news today SALT LAKE CITY, June 01, Abo Gahda 06/01/17 08:32:23 AM
#36943  Sticky Note Great-Basin-Scientific-Issued-Second-U.S.-Patent-for-PCR-Amplification-Suppresso EnergySaver 05/29/17 01:07:57 PM
#31968  Sticky Note Great Basin Scientific Receives FDA 510(k) Clearance for kontente 04/04/17 09:20:53 AM
#37023   Gonna need another Reverse Split soon. BRoberts1982 06/23/17 12:03:16 PM
#37022   What's taking this SCAM so long to get wickerman 06/20/17 05:06:05 PM
#37021   Great Basin prices $2.7M equity offering; shares down Shky 06/20/17 02:26:55 PM
#37020   Balls of steel Jiminy Cricket 06/20/17 09:50:58 AM
#37019   I may buy this POS below .25 Atlanta1 06/20/17 09:47:23 AM
#37018   Yes I agree! MASSIVE DILUTION is still going on. BRoberts1982 06/19/17 09:36:46 AM
#37017   Yes over 1.3 billion LESS shares outstanding, Great Drugdoctor 06/18/17 06:58:31 PM
#37016   LOL - Where did I say BRoberts1982 06/18/17 04:48:16 PM
#37015   LOL - S1 filing is NOT CONVERTIBLE DEBENTURES... Drugdoctor 06/18/17 12:38:53 PM
#37014   NOPE The dilution is still MASSIVE. BRoberts1982 06/18/17 12:15:16 PM
#37013   Agreed-Dilution-controlled now..Post-Split-Dilution-rates-for-last-2-REVERSE-Spl Drugdoctor 06/18/17 12:08:09 PM
#37012   Man, to go to the extent of trying BRoberts1982 06/18/17 11:26:49 AM
#37011   FDA CLEARANCE EVER COMING?? johntorich 06/18/17 09:12:11 AM
#37010   (((WOWSERS)))---$GBSN.37---Post-Split-Dilution-rates-for-last-2-REVERSE-Splits-Compared Drugdoctor 06/17/17 12:35:10 PM
#37009   So you just aren't going to compare dilution Drugdoctor 06/17/17 11:56:34 AM
#37008   I wonder why you think the current (AND BRoberts1982 06/17/17 11:49:49 AM
#37007   So you won't show the dilution rate from Drugdoctor 06/17/17 11:43:48 AM
#37006   OK NEXT, a GBSN history BRoberts1982 06/17/17 11:30:48 AM
#37005   CEO Number UNO(1), Ryan Ashton!!!!!!!!!!! Id StockUser 06/16/17 03:03:17 PM
#37004   No, I didn't say, you said it... next... Drugdoctor 06/16/17 02:00:41 PM
#37003   So let me understand this correctly, you are BRoberts1982 06/16/17 09:02:41 AM
#37002   CEO #1, Ryan Ashton!!!!!!!!!! Id StockUser 06/16/17 08:55:29 AM
#37001   Please research the share count this same amount Drugdoctor 06/15/17 02:09:27 PM
#37000   There is NO DILUTION .... scratch that. BRoberts1982 06/15/17 10:10:07 AM
#36999   GBSN dilution has NOT been minor BRoberts1982 06/15/17 09:02:27 AM
#36998   i wish longs the best ----i still remember tmonkey 06/15/17 06:39:28 AM
#36997   Yes, we all know the record here... but Drugdoctor 06/15/17 06:34:30 AM
#36996   everybody can see this and it hasnt boosted tmonkey 06/15/17 06:31:14 AM
#36995   There are $3.00 floors on most of the Drugdoctor 06/15/17 06:23:45 AM
#36994   give em time---look again in a month ----tmonkey tmonkey 06/15/17 06:18:06 AM
#36993   No actually - previous reverse splits would have Drugdoctor 06/15/17 05:57:38 AM
#36992   same thing could have been said how many tmonkey 06/15/17 04:37:09 AM
#36991   Yes, dilution has been minor, compared to previous Drugdoctor 06/14/17 10:14:18 PM
#36989   and the get away with it!!---got to love it-------tmonkey tmonkey 06/14/17 09:39:48 AM
#36988   It is in the 8K's. BRoberts1982 06/14/17 09:32:11 AM
#36987   sure makes the current market cap look awfully small. Atlanta1 06/14/17 09:31:28 AM
#36986   Where did u find these information? Thanks. ipokeru 06/14/17 09:22:53 AM
#36985   UNO, # 1 CEO!!!! Id StockUser 06/13/17 03:57:43 PM
#36984   WATCH OUT!!! Big DUMP coming very soon IMO!!!!! Id StockUser 06/13/17 03:49:22 PM
#36983   Clearance this week? AvL 06/13/17 11:44:31 AM
#36982   $GBSN - got back in this morning sub .37 Atlanta1 06/13/17 10:53:03 AM
#36980   Nice! 24% rally on a Friday... This one's Drugdoctor 06/10/17 04:24:39 PM
#36978   and .... MORE DILUTION BRoberts1982 06/10/17 10:31:10 AM
#36977   Headed towards .0005 gbsn boston79 06/10/17 09:10:08 AM
#36974   A quality company w real revs that cares bowljam 06/09/17 03:04:37 PM
#36973   200 m again printed in last 14 days. upanddown66 06/09/17 08:32:11 AM
#36971   UNO, #1...RYAN ASHTON! Straight to LA, No stopping! Id StockUser 06/08/17 07:36:42 PM
#36970   all the bulls are gone again--this tiger NEVER-will tmonkey 06/08/17 02:48:17 AM
#36969   No. It is ALWAYS just a matter BRoberts1982 06/07/17 04:31:57 PM
#36968   I do love that logic. BRoberts1982 06/04/17 11:03:49 AM